E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
Patients and healthcare providers are advised not to use any DARZALEX products bearing batch numbers MYS7381 or STV1K01.
imphoenix82
Johnson & Johnson said the CHMP opinion is an important step towards positioning the off-the-shelf immunotherapy combination of teclistamab and daratumumab as a potential new standard of care earlier in the multiple myeloma treatment pathway.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
